Pereira, Daniel

Daniel Pereira is a partner, Co-Head of the Chemical Practice Group at Oblon, and member of the management committee. His practice focuses on client counseling, portfolio management, patent prosecution, litigation and interferences involving a wide range of technologies including battery materials (including solid electrolytes, solid-state batteries, and anode and cathode materials for lithium-ion batteries), recombinant DNA technology, genetics, immunology, enzymology, medical diagnostics, bioinformatics, microarrays, statistical data analysis, genomics, proteomics, nanotechnology, polymer chemistry, metallurgy, solar technology, imaging, medical devices, optical films, coatings, cosmetics, catalysts, ceramics, alloys, chemical engineering, optical and electronic devices. Dr. Pereira has particular expertise in the medical, biotechnology, and pharmaceutical fields.

Dr. Pereira has served as co-counsel on interferences cases, advising on issues ranging from strategies for avoiding interferences to strategies for provoking them. He has also acted as co-counsel in declared interferences. Dr. Pereira handles appeals before the Board of Patent Appeals and Interferences (BPAI), district court patent litigations, and Federal Circuit appeals, and has extensive experience providing pre-litigation and litigation avoidance counseling to clients. Additionally, Dr. Pereira assists both foreign and domestic clients of all sizes with licensing and contract negotiations, due diligence analyses and risk assessment in intellectual property asset acquisition transactions.

Prior to joining the firm, Dr. Pereira worked as a post-doctoral research scientist at the Mount Sinai School of Medicine where he conducted research in the fields of neurodegeneration and transgenic mouse models of human disease. While obtaining his degrees, he studied gene expression and gene therapy and performed research in the area of leukemia pathogenesis.